Roche (RHHBY.PK) said the U.S. Food and Drug Administration or FDA has accepted the company's Biologics License Application for pertuzumab and granted Priority Review.
The proposed indication is pertuzumab in combination with Herceptin and docetaxel chemotherapy for people with HER2-positive metastatic or locally recurrent, unresectable breast cancer, who have not received previous treatment or whose disease has relapsed after adjuvant therapy. The FDA confirmed the action date is June 8, 2012.
The pertuzumab application is based on results from the pivotal Phase III CLEOPATRA study. The study showed a 6.1 month improvement in median progression-free survival for people who received a pertuzumab-based regimen compared to those who received Herceptin and chemotherapy alone. Moreover, people who received the combination also underwent a 38 percent reduction in the risk of their disease worsening or death, the company added.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.